The Petri Dish: Boston biotech scores FDA approval, antiviral maker stops 3 studies

Chiesi Global Rare Diseases, a Boston-based business unit of Italian biopharma firm Chiesi Group, scored an approval from the U.S. Food and Drug Administration for a skin disorder drug. Plus, other life sciences news you may have missed.